Tenecteplase in the Extended 4.5–24-Hour Window for Acute Ischemic Stroke: An Updated Meta-Analysis of RCTs with EVT-Stratified Subgroup Analysis

Тенектеплаза в расширенном временном окне 4,5–24 часа при остром ишемическом инсульте: обновлённый метаанализ рандомизированных контролируемых исследований с анализом подгрупп по применению эндоваскулярной тромбэктомии
Sadia Qazi, Arsalan Ahmed, Mazhar Ali, Muhammad Usman Iqbal, Eshal Atif, Zain Ali, Abdullah Imtiaz, N. Shafi, Muhammad Hassan Imtiaz, Mehmoona Zahid, Muhammad Sharjeel Abbas, Muhammad Atif Mazhar
2026-05-26

Acute ischemic strokeEndovascular thrombectomyExtended treatment windowRandomized controlled trialsTenecteplase
Background: The efficacy of tenecteplase for acute ischemic stroke (AIS) beyond 4.5 h remains uncertain, particularly across care pathways with and without endovascular thrombectomy (EVT). We performed an updated systematic review and meta-analysis using an EVT-stratified framework. Methods: PubMed, Embase, Scopus, and the Cochrane Library were searched through February 2026 for randomized controlled trials comparing tenecteplase with control in imaging-selected patients with AIS presenting 4.5–24 h from last known well. The primary outcome was excellent functional outcome (mRS 0–1) at 90 days. Secondary outcomes were good functional outcome (mRS 0–2), recanalization, early neurological improvement, symptomatic intracranial hemorrhage, and 90-day mortality. Random-effects models with Hartung–Knapp adjustment were used. Subgroup analyses by EVT availability were interpreted as exploratory because of the limited number of trials. Results: Five trials including 1844 patients were analyzed. Tenecteplase improved excellent functional outcome (RR 1.25, 95% CI 1.10–1.42; p = 0.0005) with no heterogeneity (I2 = 0%) and no interaction by EVT status (p-interaction = 0.961). Good functional outcome was not significantly different overall (RR 1.10, 95% CI 0.97–1.24; p = 0.135). Significant subgroup interactions were observed for recanalization (p-interaction = 0.004) and early neurological improvement (p-interaction = 0.002), with benefits concentrated in non-EVT settings. However, the larger effect on recanalization did not translate proportionally into functional recovery, supporting separation of vessel-opening outcomes from patient-centered outcomes. Symptomatic intracranial hemorrhage showed a nonsignificant increase in four estimable studies (RR 1.88, 95% CI 0.94–3.78; p = 0.074), whereas 90-day mortality did not differ significantly (RR 1.11, 95% CI 0.85–1.43; p = 0.43). Conclusions: In imaging-selected AIS presenting 4.5–24 h after onset, tenecteplase improved excellent functional outcome irrespective of EVT availability, while benefits for recanalization and early neurological improvement were largely confined to non-EVT settings. Because recanalization is an intermediate endpoint, these findings should not be interpreted as proof of a proportional clinical benefit. Future extended-window trials should specify EVT status.
1
An updated meta-analysis of five randomized trials involving 1,844 imaging-selected patients assessed tenecteplase between 4.5 and 24 hours after stroke onset.
2
Overall good functional outcome (mRS 0–2) was not significantly improved (RR 1.10, 95% CI 0.97–1.24; p = 0.135).
3
Recanalization and early neurological improvement benefits were concentrated in non-EVT settings, but greater vessel opening did not translate proportionally into functional recovery.
4
Symptomatic intracranial hemorrhage showed a nonsignificant increase, while 90-day mortality did not differ significantly between tenecteplase and control groups.
5
Tenecteplase significantly improved excellent functional outcome (mRS 0–1) at 90 days versus control (RR 1.25, 95% CI 1.10–1.42; p = 0.0005), without heterogeneity.
6
The improvement in excellent functional outcome showed no interaction with EVT availability (p-interaction = 0.961), suggesting benefit across EVT-stratified care pathways.

Imaging-selected patients with acute ischemic stroke presenting 4.5–24 hours after last known well, treated with tenecteplase with or without endovascular thrombectomy

Tenecteplase efficacy and safety, including functional recovery, recanalization, early neurological improvement, symptomatic intracranial hemorrhage, and 90-day mortality, stratified by EVT availability

Publication Details
Publication Date
2026-05-26
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Sadia Qazi
Arsalan Ahmed
Mazhar Ali
Muhammad Usman Iqbal
Eshal Atif
Zain Ali
Abdullah Imtiaz
N. Shafi
Muhammad Hassan Imtiaz
Mehmoona Zahid
Muhammad Sharjeel Abbas
Muhammad Atif Mazhar
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%